AT291247B - Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen - Google Patents
Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onenInfo
- Publication number
- AT291247B AT291247B AT768868A AT768868A AT291247B AT 291247 B AT291247 B AT 291247B AT 768868 A AT768868 A AT 768868A AT 768868 A AT768868 A AT 768868A AT 291247 B AT291247 B AT 291247B
- Authority
- AT
- Austria
- Prior art keywords
- pyrazin
- imidazo
- ones
- preparation
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65904267A | 1967-08-08 | 1967-08-08 | |
| US72803368A | 1968-05-09 | 1968-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT291247B true AT291247B (de) | 1971-07-12 |
Family
ID=27097746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT768868A AT291247B (de) | 1967-08-08 | 1968-08-06 | Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3507866A (de) |
| AT (1) | AT291247B (de) |
| BE (1) | BE719154A (de) |
| CH (1) | CH516574A (de) |
| DE (1) | DE1795062A1 (de) |
| DK (1) | DK123484B (de) |
| ES (1) | ES356976A1 (de) |
| FR (2) | FR1578366A (de) |
| GB (1) | GB1193035A (de) |
| IL (1) | IL30463A0 (de) |
| NL (1) | NL6810650A (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US20050090505A1 (en) * | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) * | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| US7923041B2 (en) * | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| SI2069352T1 (sl) * | 2006-08-02 | 2013-12-31 | Cytokinetics, Inc. | Določene kemijske entitete, sestavki in postopki |
| DK2583970T3 (en) * | 2006-08-02 | 2015-11-16 | Cytokinetics Inc | Certain chemical entities, compositions, and methods comprising imidazopyrimidines |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| ZA200902382B (en) * | 2006-10-19 | 2010-08-25 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| WO2008121333A1 (en) * | 2007-03-30 | 2008-10-09 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| KR101903925B1 (ko) | 2009-10-26 | 2018-10-02 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| WO2013010015A2 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| EP3659599B1 (de) | 2011-10-19 | 2022-12-21 | Signal Pharmaceuticals, LLC | 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on zur verwendung zur behandlung von glioblastoma multiforme |
| MX363034B (es) | 2011-12-02 | 2019-03-06 | Signal Pharm Llc | Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida de las mismas y metodos de su uso. |
| CN104271159B (zh) | 2012-02-24 | 2017-11-28 | 西格诺药品有限公司 | 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| UA120343C2 (uk) | 2012-12-17 | 2019-11-25 | Періон Сайєнсіз, Інк. | Похідні хлорпіразинкарбоксаміду, які мають активність блокування епітеліальних натрієвих каналів |
| EP2931712B8 (de) | 2012-12-17 | 2018-05-23 | Parion Sciences, Inc. | 3,5-diamino-6-chlor-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazin-2-carboxamid verbindungen |
| EP3202403A1 (de) | 2013-01-16 | 2017-08-09 | Signal Pharmaceuticals, LLC | Substituierte pyrrolopyrimidine, zusammensetzungen davon und behandlungsverfahren damit |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
| WO2014172430A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| KR102459285B1 (ko) | 2013-04-17 | 2022-10-27 | 시그날 파마소티칼 엘엘씨 | 1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법 |
| KR102271344B1 (ko) | 2013-04-17 | 2021-07-01 | 시그날 파마소티칼 엘엘씨 | 디하이드로피라지노-피라진을 사용한 암의 치료 |
| SG10201708111YA (en) | 2013-04-17 | 2017-11-29 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| TWI654979B (zh) | 2013-04-17 | 2019-04-01 | 美商標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| MX2015015880A (es) | 2013-05-29 | 2016-05-31 | Signal Pharm Llc | Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso. |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| EP3131552B1 (de) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Verfahren zur behandlung von krebs anhand einer tor-kinasehemmerkombinationstherapie |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
-
1968
- 1968-05-09 US US728033A patent/US3507866A/en not_active Expired - Lifetime
- 1968-07-26 NL NL6810650A patent/NL6810650A/xx unknown
- 1968-07-29 IL IL30463A patent/IL30463A0/xx unknown
- 1968-08-05 DE DE19681795062 patent/DE1795062A1/de active Pending
- 1968-08-05 GB GB37296/68A patent/GB1193035A/en not_active Expired
- 1968-08-06 ES ES356976A patent/ES356976A1/es not_active Expired
- 1968-08-06 AT AT768868A patent/AT291247B/de not_active IP Right Cessation
- 1968-08-07 CH CH1183068A patent/CH516574A/de not_active IP Right Cessation
- 1968-08-07 DK DK379768AA patent/DK123484B/da unknown
- 1968-08-07 BE BE719154D patent/BE719154A/xx unknown
- 1968-08-08 FR FR1578366D patent/FR1578366A/fr not_active Expired
- 1968-11-08 FR FR173159A patent/FR8409M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1193035A (en) | 1970-05-28 |
| ES356976A1 (es) | 1970-10-16 |
| BE719154A (de) | 1969-02-07 |
| FR8409M (de) | 1971-03-31 |
| DE1795062A1 (de) | 1972-03-30 |
| US3507866A (en) | 1970-04-21 |
| FR1578366A (de) | 1969-08-14 |
| DK123484B (da) | 1972-06-26 |
| IL30463A0 (en) | 1968-09-26 |
| CH516574A (de) | 1971-12-15 |
| NL6810650A (de) | 1969-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT291247B (de) | Verfahren zur Herstellung von neuen 1H-Imidazo[4,5-b]pyrazin-2-onen | |
| CH505118A (de) | Verfahren zur Herstellung von 1,2,4-Triazin-5-onen | |
| AT275521B (de) | Verfahren zur Herstellung von neuen 1,4-Dihydropyridinderivaten | |
| CH481110A (de) | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen | |
| CH502364A (de) | Verfahren zur Herstellung von neuen 1,2,4-Oxadiazolen | |
| AT281836B (de) | Verfahren zur Herstellung von neuen 2-Methyl-3-carbonsäureamido-chinoxalin-di-N-oxiden-(1,4) | |
| AT277221B (de) | Verfahren zur Herstellung von neuen 5-Nitro-2-furyl-2-isoxazolin-derivaten | |
| CH496022A (de) | Verfahren zur Herstellung von neuen N,N'-Diglycidyl-Verbindungen | |
| AT291250B (de) | Verfahren zur Herstellung von neuen 5-NR<1>R<2> -6-Chlor-1H-imidazo[4,5-b]pyrazin-2-onen | |
| AT277985B (de) | Verfahren zur Herstellung von neuen Nitro-furan-, -thiophen- oder -pyrrol-derivaten | |
| CH498132A (de) | Verfahren zur Herstellung neuer Pyrido (1,2-a)-s-triazindione | |
| AT284128B (de) | Verfahren zur Herstellung von neuen 2-Halogenmethyl-3-carbansäureamido-chinoxalin-di-N-oxiden-(1,4) | |
| AT280271B (de) | Verfahren zur Herstellung von neuen Cumarinyl-v-triazoloxydderivaten | |
| AT281838B (de) | Verfahren zur Herstellung von neuen 2-Isothiuronium-methyl-3-carbonsäureamido-chinoxalin-di-N-oxid-(1,4)-halogeniden | |
| AT299172B (de) | Verfahren zur Herstellung von neuen Naphthylisopropyl-Derivaten | |
| CH489525A (de) | Verfahren zur Herstellung von 1,8-Naphthyridinderivaten | |
| AT283356B (de) | Verfahren zur Herstellung von neuen 1,2,4-Oxdiazolidin-Derivaten | |
| CH508645A (de) | Verfahren zur Herstellung von neuen 5-substituierten y-Carbolinderivaten | |
| CH453370A (de) | Verfahren zur Herstellung von neuen 5,6-Dihydro-6-oxo-pyrido (2,3-b)(1,4)benzoxazepinen | |
| AT290026B (de) | Verfahren zur Herstellung von neuen 22-Amino-23,24-bisnorcholanderivaten | |
| AT293634B (de) | Verfahren zur Herstellung von neuen 17α-Acyloxy-11β-methyl-19-norpregn-4-en-3,20-dionen | |
| CH522619A (de) | Verfahren zur Herstellung von neuen Derivaten von 2a,3a-Epithioandrostanen | |
| AT291967B (de) | Verfahren zur Herstellung von neuen N-Phenyl-N-2-fluor-1,1,2,2,-tetrachloräthylsulfenyl-sulfamiden | |
| CH469729A (de) | Verfahren zur Herstellung von neuen 4,9-Dihydrothieno-(2,3-b)-benzo-(e)-thiepinderivaten | |
| AT281020B (de) | Verfahren zur Herstellung von neuen 3-Imino-1,2-benzisothiazolinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ELJ | Ceased due to non-payment of the annual fee |